InCrowd Equity make Investing in Early Stage Companies both Exciting and Easy
With 78% of US population owning a mobile devices in 20131 and global mobile penetration at 90%2, InCrowd's milestone on the adoption of its on-demand methodology further reflects transformation of the market research industry where long lead-time projects several times a year are giving way to a more agile, do-it-yourself (DIY) approach that captures insights on demand via mobile formats, and enables faster daily business decision making.
“InCrowd is the best platform and program for answering surveys," said a physician who is among the over 1.8 million verified members of InCrowd's “Crowd." “I stopped completing other surveys that cannot be done on a mobile device or with an app." Another physician related that “withInCrowd, the questions are very direct and to the point. I feel my answers mean more here."
InCrowd was first to market in 2011 with a real-time data offering that combined self-service real time technology, access to a large Crowd of verified healthcare professionals, and deep life science expertise. Combining methodological rigor with a friendly, easy to use mobile interface, InCrowd's average microsurvey requests and receives an average of 50 respondents per survey, delivering full results in less than 8 hours. The approach's speed and simplicity has fundamentally changed the industry by providing professional quality data in situations where it was previously impossible to get timely market information.
Today, InCrowd has 18 of the top 20 pharmaceutical firms as customers and has just finished its most successful quarter in company history with a record number of answers delivered to clients. Through its powerful mobile microsurvey methodology and analytics engine, InCrowd enables clients to reach 1.8M healthcare professionals on-demand throughout the United States and around the globe in 20 languages.
“In just four years since we issued our first answer for customers, we've crossed a major threshold and so has our industry," said Janet Kosloff, CEO and co-founder of InCrowd. “We're committed to further innovation in making life science market insights even easier to achieve and more meaningfully delivered."
InCrowd provides on-demand answers from validated experts, connecting life sciences companies directly with prescribers, patients, and other screened and validated healthcare professionals around the globe. Our easy-to-use proprietary web-based application allows clients to ask questions of specific respondent groups – “Crowds" – in the form of 2-5 minute online microsurveys. Responses are available in real time through a password-protected account, with the needed answers delivered within hours or days, not weeks or months.
For more information, visit: www.incrowdnow.com
InCrowd Media Contact:
Steven Handy, Director of Marketing
Mary Kae Marinac, PR Representative for InCrowd
Disclaimer: Trading foreign exchange on margin carries a high level of risk and may not be suitable for all investors. The high degree of leverage can work either against or for you. Before deciding to trade foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain a loss of some or all of your initial investment and, therefore, you should not invest money you cannot afford to lose. You should be aware of all the risks associated with foreign exchange trading and seek advice from an independent financial adviser if you have any doubts.
Company Name: PublicWire Contact Person: Dave Donlin Email: firstname.lastname@example.org Phone: 4074906635 Address:5850 TG Lee Blvd, Suite 300 City: Orlando State: FL Country: United States Website: http://publicwire.com